Want to see JNJ full AI Analyst Report?
JNJ Stock Chart & Stats
$234.18
-$4.08(-2.79%)
At close: 4:00 PM EST
$234.18
-$4.08(-2.79%)
Day’s Range― - ―
52-Week Range$149.74 - $251.71
Previous CloseN/A
Volume3.80M
Average Volume (3M)8.06M
Market Cap
$549.78B
Enterprise Value$597.07B
Total Cash (Recent Filing)$22.05B
Total Debt (Recent Filing)$54.99B
Price to Earnings (P/E)26.5
Beta0.01
Next Earnings
Jul 15, 2026EPS Estimate
2.85Next Dividend Ex-DateN/A
Dividend Yield2.5%
Share Statistics
EPS (TTM)8.67
Shares Outstanding2,407,217,000
10 Day Avg. Volume8,877,223
30 Day Avg. Volume8,064,041
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue6.20
Enterprise Value/Gross Profit8.96
Enterprise Value/Ebitda17.83
Forecast
1Y Price Target
$264.62Price Target Upside13.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)11.58
Revenue Forecast (FY)$100.95B
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthJohnson & Johnson’s multi-year revenue expansion demonstrates durable commercial momentum and diversification across Pharma and MedTech. A steadily growing top line supports ongoing R&D, launch funding and capital commitments, reducing reliance on any single product for medium-term growth.
High, Sustainable MarginsConsistently high gross and operating margins indicate structural pricing power and efficient scale across the portfolio. Strong margin architecture supports internal funding for launches, dividend continuity and the ability to invest in manufacturing and R&D without immediate capital-market dependence.
Deep Pipeline & Launch MomentumA broad set of growing brands and recent approvals/launches showcases sustainable innovation and commercialization capability. Multiple $1B+ platforms and new assets (ICOTYDE, TREMFYA, oncology launches) provide durable levers to offset legacy declines and underpin multi-year revenue re-acceleration.
Bears Say
STELARA Sales ErosionA 61.7% drop in a legacy immunology franchise from biosimilars and class changes is a structural revenue loss that pressures near-term growth. Replacing such volume requires successful commercialization of multiple new launches, adding execution risk over the next several quarters.
Margin Deleverage From Launchs/CostsNotable margin declines reflect sustained heavier launch investments, mix shifts and one-time items. If elevated SG&A and launch spending persist, operating leverage will be muted, constraining profit conversion and making margin recovery dependent on successful scale-up of new products.
Cash-Flow Volatility & Soft Early FCFDeclining FCF and low OCF-to-net-income ratio point to timing or working-capital swings and less consistent cash conversion. A soft Q1 FCF run-rate increases execution risk to meet ~$21B full-year FCF guidance, potentially limiting discretionary capital allocation flexibility in the near term.
Johnson & Johnson News
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $149.74 and its highest was $251.71 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is $549.78B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 15, 2026 which is in 13 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 14, 2026. The company reported $2.7 earnings per share for the quarter, beating the consensus estimate of $2.677 by $0.023.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.34 which represents an annual dividend yield of 2.5%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.85.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,407,217,000 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.7 in its last earnings report, beating expectations of $2.677. Following the earnings report the stock price went up 0.899%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$264.62 (13.00% Upside)
$264.62 (13.00% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 525.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 6.7%
Last 30 Days ▲ 6.7%
News Sentiment
Very Bullish
Bullish news 82%
Bearish news 18%
Bearish news 18%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.00%
12-Months-Change
Fundamentals
Return on Equity
26.26%
Trailing 12-Months
Asset Growth
3.73%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
JNJ Company Deck
JNJ Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a broadly positive commercial and pipeline story: strong top-line operational growth, multiple high-growth products (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT, TREMFYA) and successful new launches (ICOTYDE, INLEXZO) with raised full‑year guidance and clear long‑term targets (line of sight to double‑digit growth by decade end). Offsetting these positives were significant short‑term headwinds—most notably a steep STELARA decline, GAAP EPS volatility driven by prior-year one‑time items, margin deleverage from heavier launch investments and a soft Q1 free cash flow run‑rate. Management emphasized confidence in recovery/acceleration through the year, substantial R&D and manufacturing investments, and multiple upcoming catalysts, leading to an overall constructive outlook despite near‑term profitability and comparability pressures.View all JNJ earnings summariesJNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
JNJ Stock 12 Month Forecast
Average Price Target
$264.62
▲(13.00% Upside)
Technical Analysis
Ownership Overview
0.04% Insiders
18.84% Mutual Funds
0.02% Other Institutional Investors
57.37% Public Companies and Individual Investors